Open Nav

Please submit your session questions in advance at

Resverlogix Corp.

Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while maintaining a well described safety profile.

  • Date:Tuesday, February 12
  • Time:2:00 PM - 2:15 PM
  • Room:Herald/Soho
  • Location:7th Floor
  • Session Type:Company Presentation
  • Please submit your session questions in advance:

    Click here.

  • Company Presentation - Presentation Type:Publicly Traded Company
  • Submission ID:22460
  • Goal for Presentation:Future of drug development with epigenetics
  • Company
  • Company HQ City:Calgary
  • Company HQ State:Alberta
  • Company HQ Country:Canada
  • Ticker:RVX
  • Exchange:TSX
  • CEO/Top Company Official:Donald McCaffrey
  • Year Founded:2001
  • Main Therapeutic Focus:Cardiovascular
  • Lead Product in Development:Apabetalone
  • Development Phase of Primary Product:Phase III
Donald McCaffrey
Resverlogix Corp.